ライフサイエンスコーパス: thiotepa

1 eived combined chemotherapy of docetaxel and thiotepa.

2 administration of the chemotherapeutic drug thiotepa.

3 rapy with cyclophosphamide, carboplatin, and thiotepa.

4 ulfan (n = 94) combined with fludarabine +/- thiotepa.

5 sduced cells were treated with four doses of thioTEPA (10 mg/kg) given over 7 weeks.

6 (included total-body irradiation [1375 cGy], thiotepa [10 mg/kg], and cyclophosphamide [100 mg/kg]).

7 ification with cyclophosphamide 1,500 mg/m2, thiotepa 125 mg/m2, and carboplatin 200 mg/m2 by IV cont

8 ous infusion of cyclophosphamide 1.5 g/m2/d, thiotepa 125 mg/m2/d, and carboplatin 200 mg/m2/d follow

9 (2) [day 1], carmustine 400 mg/m(2) [day 2], thiotepa 2 x 5 mg/kg [days 3 and 4], and infusion of ste

10 Intensive chemotherapy consisted of thiotepa (250 mg/m(2)/d D9; D8; D7), busulfan (8 mg/kg D

11 rexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three g

12 rexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three g

13 in 1 h intravenous infusions, days 2 and 3; thiotepa 30 mg/m(2), 30 min intravenous infusion, day 4)

14 Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -

15 Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused

16 tal dose of 8.4 g/m2 with leucovorin rescue; thiotepa 35 mg/m2; vincristine 1.4 mg/m2; dexamethasone;

17 1), cytarabine 3 g/m(2) (days 2 and 3), and thiotepa 40 mg/m(2) (day 3).

18 ASCT (carmustine 400 mg/m(2) on day -6, and thiotepa 5 mg/kg every 12 h on days -5 and -4, followed

19 ose 5% solution in a 1-2 h infusion, day -6; thiotepa 5 mg/kg in saline solution in a 2 h infusion ev

20 ), followed by cyclophosphamide 6,000 mg/m2, thiotepa 500 mg/m2, and carboplatin 800 mg/m2 (CTCb) wit

21 ion cycle of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/ m2), and carboplatin (800 mg/m2) (CTCb

22 00 mg/m2), carmustine (BCNU; 450 mg/m2), and thiotepa (720 mg/m2) (CBT regimen).

23 actionated 15 Gy)/melphalan (180 mg/m(2)) or thiotepa (900 mg/m(2))/carboplatin (1,500 mg/m(2)).

24 radiotherapy and a myeloablative regimen of thiotepa (900 mg/m2) plus carboplatin (1,500 mg/m2), wit

25 ic agents (ie, methotrexate, cytarabine, and thiotepa) administered by a variety of schedules either

26 ble of penetrating the blood-brain barrier - thioTEPA and 5-fluorouracil - influence the normal proce

27 -dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transpla

28 intravenous infusion, day 2) and carmustine-thiotepa and autologous HSCT (carmustine 400 mg/m(2) in

29 HCT-ASCT with thiotepa and carmustine is an effective treatment option

30 atin, thiotepa, and etoposide (16 patients), thiotepa and etoposide (three patients), or thiotepa, et

31 ery proceeded to high-dose chemotherapy with thiotepa and etoposide and autologous peripheral blood s

32 The combination of high-dose thiotepa and etoposide has activity against a variety of

33 oidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will

34 hat nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therap

35 sulfan (busulfan in 1 patient), fludarabine, thiotepa, and anti-thymocyte globulin or alemtuzumab con

36 lternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we eva

37 hamide (original protocol) or with busulfan, thiotepa, and cyclophosphamide (modified protocol).

38 single course of high doses of carboplatin, thiotepa, and cyclophosphamide plus transplantation of a

39 of hyperfractionated total body irradiation, thiotepa, and cyclophosphamide.

40 ng with fractionated total-body irradiation, thiotepa, and cyclophosphamide.

41 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan.

42 12 Gy TBI and etoposide versus fludarabine, thiotepa, and either busulfan or treosulfan.

43 rapy was then administered with carboplatin, thiotepa, and etoposide (16 patients), thiotepa and etop

44 chemotherapy that incorporated carboplatin, thiotepa, and etoposide followed by ABMR.

45 received one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic st

46 evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue

47 ng conditioning with total body irradiation, thiotepa, and fludarabine.

48 fractionated total body irradiation (HFTBI), thiotepa, and fludarabine.

49 demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is t

50 disease; use of fludarabine, melphalan, and thiotepa; and receiving no pre-transplantation condition

51 matopoietic cells were resistant in vitro to thioTEPA at multiple concentrations.

52 ed polychemotherapy followed by age-tailored thiotepa-based conditioned autologous stem cell transpla

53 herapy and/or radiotherapy were treated with thiotepa-based HDC regimens followed by ASCR.

54 hamide (BU/CY), busulfan plus melphalan plus thioTEPA (BUMELTT), or melphalan before transplant.

55 ts with advanced leukemia received high-dose thiotepa, busulfan, and cyclophosphamide as a preparativ

56 The preparative regimen consisted of thiotepa, busulfan, and cyclophosphamide.

57 novel consolidation high-dose chemotherapy (thiotepa, busulfan, cyclophosphamide) and autologous ste

58 diotherapy (WBRT) or high-dose chemotherapy (thiotepa-busulfan-cyclophosphamide) with autologous stem

59 h methotrexate-cytarabine plus rituximab and thiotepa, but infective complications were similar in th

60 The three patients treated with thiotepa/carboplatin relapsed 3 to 4 months after transp

61 Four patients received thiotepa/carboplatin: two were in CR and remain so, and

62 mbination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=

63 st induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m(2) on day

64 luded older age (P <.01), busulfan/melphalan/thiotepa conditioning (P <.01), interleukin-2 (P =.02),

65 es of adjuvant chemotherapy with intrathecal thiotepa, consolidation chemotherapy, and autologous ste

66 t cross the blood-brain barrier, followed by thiotepa-containing conditioning and autologous stem-cel

67 overall results are encouraging, mostly when thiotepa-containing conditioning regimens are used, both

68 sponse proceeded with consolidation HDC with thiotepa, cyclophosphamide, and busulfan, followed by AS

69 cGy (n = 1), fludarabine/melphalan (n = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarab

70 randomized to receive tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carbo

71 sponse rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (

72 thiotepa and etoposide (three patients), or thiotepa, etoposide, and carmustine (BCNU; one patient).

73 = 7), thiotepa/cyclophosphamide (n = 7), and thiotepa/fludarabine (n = 1).

74 22-38), patients treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38

75 ro, nor on the antitumor activity of 5-FU or thiotepa in BALB/c mice implanted with P388 leukemia cel

76 ncrease resistance of hematopoietic cells to thioTEPA-induced cytotoxicity.

77 G1 protein protects hematopoietic cells from thioTEPA-induced DNA damage and suggest that a high leve

78 may provide an novel approach to preventing thioTEPA-induced toxicity of primary hematopoietic cells

79 N,N',N"-Triethylenethiophosphoramide (thioTEPA) induces the formation of amino-ethyl adducts o

80 tion with clinical efficacy of docetaxel and thiotepa on metastatic breast cancer patients; and metas

81 randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121).

82 efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy

83 ukocytes, hemoglobin, and platelet counts of thioTEPA-treated Fpg mice were significantly higher than

84 lineage regeneration after high-dose 5-FU or thiotepa treatment in BALB/c mice.

85 ntation (HSCT) after a preparation combining thiotepa, treosulfan, and fludarabine.

86 lan (Mel) in 123 subjects; (2) Flu, Mel, and thiotepa (TT) in 28 subjects; (3) Flu and busulfan (Bu)

87 The ablative regimens included: (1) thiotepa (TT)/cyclophosphamide (CTX)/carboplatin (CP; n

88 ly, asymptomatic patients were enrolled in a thiotepa up-front therapeutic window.

89 Response rate to thiotepa was 78%.

90 thioTEPA was found to yield a pronounced dose-related in